Memaxa

Memantine Hydrochloride, the active ingredient in Memaxa, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memaxa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memaxa belongs to the NMDA receptor antagonist class and is used in the management of neurodegenerative dementia. - Alzheimer’s disease (moderate to severe): improves cognition, daily functioning, and overall clinical status. - Behavioral disturbances in Alzheimer’s disease: may reduce agitation, aggression, and related symptoms. - Cognitive impairment associated with Alzheimer’s disease: helps maintain memory and attention functions.

Memaxa may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Fatigue: feeling unusually tired or lacking energy.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Allergic reactions: including rash, itching, swelling, or anaphylaxis.

Before initiating Memaxa, clinicians should consider several safety aspects. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Concomitant NMDA antagonists: avoid co‑administration to reduce additive CNS effects. - History of seizures: observe closely for increased seizure activity. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Memaxa can interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Amantadine: combined use may increase CNS adverse effects. - Dextromethorphan: may potentiate neuropsychiatric side effects. - High‑dose quinidine: can raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance blood pressure elevation. - Anticholinergic agents: could diminish memantine’s cognitive benefits. - Carbamazepine: may reduce memantine levels, affecting efficacy.